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Abstract: Uveal melanoma (UM) is the most common primary intraocular tumor in adults with
high mortality. In order to improve prognosis and survival of UM patients, it is critical to inhibit
tumor progression and metastasis as early as possible after the initial presentation/diagnosis of the
disease. Sustained local delivery of antitumor therapeutics in the posterior region can potentially
achieve long-term UM inhibition, improve target therapeutic delivery to the posterior segments, as
well as reduce injection frequency and hence improved patient compliance. To address the highly
unmet medical need in UM therapy, a bioinspired in situ gelling hydrogel system composed of
naturally occurring biopolymers collagen and hyaluronic acid was developed in the present research.
Curcumin with anti-cancer progression, anti-metastasis effects, and good ocular safety was chosen
as the model therapeutic. The developed in situ gelling delivery system gelled at 37 ◦C within
two minutes and demonstrated excellent biocompatibility and slow degradation. The curcumin-
loaded nanoparticle/hydrogel composite was able to sustain release payload for up to four weeks.
The optimized nanoparticle/hydrogel composite showed effective inhibition of human UM cell
proliferation. This novel nanoparticle/in situ hydrogel composite demonstrated a great potential for
the treatment of the rare and devastating intraocular cancer.
Keywords: in situ hydrogel; nanoparticle/hydrogel composite; sustained delivery; curcumin;
uveal melanoma
1. Introduction
Uveal melanoma (UM) is considered a rare disease yet the most common primary
intraocular tumor with high metastasis and lethality in adults [1,2]. Treatment modalities in-
cluding globe-preserving therapies (e.g., proton beam radiotherapy, plaque brachytherapy)
and enucleation have been commonly used. Despite the aggressive treatment strategies,
a high recurrence rate, in particular following transscleral resection (up to 32.6%), has
remained a challenge [3–5]. Moreover, nearly a half of UM patients eventually developed
metastatic diseases (primarily in the liver) that are resistant to systemic chemo- and im-
munotherapy, leading to poor prognosis and high mortality [6]. Up to now, there has been
a lack of effective treatment to prevent UM metastasis. Accordingly, it is considered that
early detection and intervention may be critical to improve prognosis and survival of UM.
The uvea is one of the most capillary-rich tissues of the body. Most UM occurs in the
posterior segments such as choroid (~90%), iris (~5%) and ciliary body (~5%) [7,8]. Due
to the lack of lymphatic vessels in the choroid, primary UM metastasizes almost exclu-
sively via the hematogenous route [9,10]. As a result, effective suppression of molecular
mechanisms that activate angiogenesis, tumor cell mobility and invasion, has demon-
strated the potential in improving UM therapy [11–13]. For example, regulator or knock-
down hypoxia-response regulating genes cyclic AMP-response-element binding protein
and hypoxia-inducible factors-1 (HIF-1), vascular endothelial growth factor (VEGF) can
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markedly decreased UM cell or tumor growth [14–18]. However, the presence of anatomi-
cal ocular barriers (e.g., cornea, blood-retina barrier) and physiological constraints (e.g.,
nasolacrimal drainage, limited capacity in the cul-de-sac of the eye) prevents about 99% of
drug administrated systemically and topically to reach the posterior segments [19]. Local
delivery of therapeutics in the posterior chamber (e.g., via intravitreal administration) can
circumvent these barriers to directly target the tumor in the posterior chamber to improve
anti-UM effect while reducing off-target toxicity. As most therapeutics require frequent
dosing due to their short half-lives in the vitreous humor, a long-acting local delivery
platform that can sustained deliver therapeutics in the posterior chamber is considered
desirable to improve therapeutic effect and patient compliance for the UM treatment.
Various nanocarriers/microcarriers with sustained drug delivery capability have
been developed in recent years for ocular use [20,21]. Due to their size, and flexible
surface functionality, nanocarriers/microcarriers offer advantages in drug delivery for the
treatment of posterior eye diseases [22,23]. However, there are disadvantages associated
with nanocarriers/microcarriers directly administrated in the posterior chamber, including
potential toxicity due to high burst drug release; rapid phagocytic clearance which may
decrease therapeutic effect; particle aggregation due to large surface area; and particle
migration which may cause ocular inflammation [23]. Currently, marketed long-acting
intravitreal implant drug products (e.g., Ozudex®, IIuvien®) are able to sustain deliver
therapeutics in the posterior segments over weeks to months. These implant products
are administrated via either an injector/applicator with a large size needle (i.e., 22-gauge)
or surgical procedures and hence poor patient compliance. Over the past decade, in
situ gelling hydrogels that can be injected as solutions via fine needles (i.e., 30-gauge
or smaller) and transform to gels/depots at the injection site, have attracted increasing
interests due to excellent injectability and improved patient compliance [24–26]. However,
the use of synthetic polymer-based hydrogels (e.g., polystyrene, poloxamer) has limited its
applications due to concerns on biodegradability and potentially triggering inflammatory
response and influencing retinal function [25,27]. Moreover, a crosslinking initiator or
catalyst (such as a metal catalyst, or photoinitiator) or ultraviolet (UV) light is often
needed to facilitate polymer crosslinking and gelation, which raises biocompatibility
concerns [28–30]. Accordingly, it is essential to develop a biodegradable and biocompatible
in situ forming hydrogel platform that gels within seconds to minutes and is capable of
releasing payload over weeks to months.
The vitreous body is mainly composed of hyaluronic acid and different types of
collagens, primarily type II collagen [31,32]. Inspired by the natural components of the vit-
reous body, an in situ gelling hydrogel delivery platform composed of naturally occurring
biopolymers such as hyaluronic acid (HA) and collagen (type II) was developed to sus-
tained release payload for UM therapy in the present research. The in situ gelling hydrogel
system provides easy administration, prolongs retention time, and prevents drug/particle
migration. Curcumin with good ocular safety was chosen as the model therapeutic. It has
been reported curcumin can regulate hypoxia-inducible factors-1α (HIF-1α) in hepatocel-
lular carcinoma cells, pituitary adenomas, and inhibits angiogenesis in zebrafish [33–36].
Curcumin also showed anti-proliferation and down-regulation of the expression of genes
involved in apoptosis, cell proliferation and transformation against various cancers (e.g.,
breast cancer, lung cancer, colorectal cancer) [37–41]. Moreover, curcumin has been shown
to induce cell death in human UM cells via the mitochondrial pathway [42]. As curcumin
is poorly water soluble, curcumin-loaded nanoparticles with a hydrophilic coating layer
were fabricated to improve its vitreous transport and cellular uptake. The curcumin-loaded
polymeric nanoparticles were incorporated in the collagen II and HA hydrogel (CO–HA
Gel) matrix. The rheological properties, payload release as well as in vitro anti-UM effect
of the developed curcumin nanoparticle/in situ hydrogel composites were investigated.
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2. Materials and Methods
2.1. Materials
Collagen (type II) from calf articular joints was purchased from Elastic Products
Company, Inc (Owensville, MO). Sodium hyaluronate (HA, molecular weight (MW): 15
MDa) was purchased from Lifecore Biomedical (Chaska, MN, USA). Eight-arm polyethy-
lene glycol (PEG) succinimidyl glutarate (tripentaerythritol) (8-arm PEG, MW: 20 kDa
and 40 kDa) were purchased from JenKem Technology USA (Plano, TX, USA). Picryl-
sulfonic acid solution (TNBS), polysorbate (Tween) 80, N-acetylcysteine (NAC), buty-
lated hydroxytoluene (BHT), glycine (ReagentPlus®, ≥99%), dichloromethane (DCM, ACS
reagent, ≥99.5%), poly(vinyl alcohol) (PVA, 87–90% hydrolyzed, MW: 30–70 kDa), su-
crose (≥99.5%), collagenase from clostridium histolyticum (1.5 kU), hyaluronidase (type II)
from sheep testes, dimethyl sulfoxide (DMSO, ACS reagent, ≥99.9%), acetonitrile (HPLC
grade, ≥99.9%), trifluoroacetic acid (TFA, HPLC grade, ≥99.0%) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Curcumin was purchased from TCI Chemicals (Port-
land, OR, USA). Methoxypoly(ethylene glycol)-b-poly(lactide-co-glycolide) (mPEG-PLGA,
L/G: 50/50, w/w; MW: 5 kDa/55 kDa) was purchased from PolySciTech®, Akina, Inc.
(West Lafayette, IN, USA). LIVE/DEADTM viability/cytotoxicity kit (for mammalian cells),
CyQUANT™ MTT cell viability assay, phosphate-buffered saline (PBS, pH 7.4), trypsin-
EDTA (0.25%) phenol red, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES,
1 M) and penicillin-streptomycin (10,000 U/mL) were purchased from Thermo Fisher
Scientific (Waltham, MA). RPMI-1640 medium (ATCC® 30-2001™) and fetal bovine serum
(FBS) (ATCC® 30-2020™) were purchased from ATCC (Manassas, VA, USA).
Human uveal melanoma (UM) cell line MP-38 (ATCC® CRL-3296) was grown and
maintained in RPMI-1640 media with 20% (v/v) FBS and 1% (v/v) penicillin-streptomycin.
Cells were cultured in an incubator supplied with 5% CO2 at 37 ◦C. The culture medium
was replaced every 2–3 days.
2.2. Preparation of Curcumin-Loaded Nanoparticles
Curcumin-loaded polymeric nanoparticles (Cur NP) were prepared via an emulsion-
solvent-evaporation method as previously reported [43]. Briefly, curcumin and mPEG-
PLGA (curcumin/mPEG-PLGA = 1:7.5, w/w) were dissolved in 2 mL of DCM. The organic
phase was added into 10 mL of an aqueous phase containing 1% (w/v) PVA to form a
primary emulsion. Following size reduction via probe sonication, DCM was removed by
evaporation and the residual solvent was further removed under reduced pressure. The
resultant NP suspension was then filtered using a 0.22 µm filter (polytetrafluoroethylene,
PTFE). NP was purified via ultra-centrifugation at 229,600× g for 1 h with distilled (DI)
water three times. The concentrated NP suspension was then lyophilized using sucrose as
the cryoprotectant (sucrose/NP: 25/1, w/w). The lyophilized NP was stored at 4 ◦C until
further use.
2.3. Characterization of Cur NP
Lyophilized Cur NP was accurately weighed, and curcumin was extracted using
200 µL of DMSO followed by acetonitrile dilution to 2 mL. The sample was then filtered
using a 0.22 µm syringe filter (PTFE) and curcumin content was determined via HPLC
(Hitachi) with a ZORBAX Eclipse XDB C18 column (5 µm, 250× 4.6 mm) (Agilent Technolo-
gies, Inc. Santa Clara, CA, USA). The HPLC mobile phase consisted of 0.1% TFA in water
and acetonitrile (40/60, v/v) with a flow rate of 1 mL/minute. The effluent was monitored
at the wavelength of 420 nm. The retention of curcumin was around 5.2 min. The detection
and quantification limits of the HPLC analytical method were 0.027 and 0.083 µg/mL,
respectively. Curcumin loading was calculated using the following Equation (1):
Dug loading (%) =
Curcumin amount in nanoparticles
Lyophilized nanoparticle weight
× 100 (1)
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The particle size and size distribution (polydispersity index, PDI), and surface charge
of NP before and after lyophilization were characterized using Zetasizer Nano ZS90
(Malvern Instruments Ltd., Malvern, UK). The backscattering angel was 173◦ with a
standard laser wavelength λ of 633 nm. The measurement of dynamic diameter (DH) is
according to the Stokes–Einstein equation as a function of the diffusion coefficient (D),
temperature (T), and viscosity (η). The measurements were carried out in triplicate.
2.4. Fabrication of CO–HA Gels and Composites
A HA solution in PBS (10 mM, pH 7.4) (5 mg/mL) was mixed with a collagen II
solution in a phosphate buffer (20 mM, pH 7.4) (5 mg/mL) at an optimized volume ratio
of 3/1 (HA/collagen). An 8-arm PEG solution in PBS (10 mM, pH 7.4) (200 mg/mL) was
then added into the mixture at a volume ratio of 1/13.5, and the blank hydrogel (CO–HA
Gel) was formed when incubating the mixture at 37 ◦C.
To form NP/CO–HA Gel composite, accurately weighed NP (either blank or Cur NP)
was added into the collagen II solution prior to mixing with other gel components (i.e., HA
and PEG). The NP/CO–HA Gel composite was then formed following the similar proce-
dure described above for the blank CO–HA Gel. To form curcumin/hydrogel composite
(Cur/CO–HA Gel), a curcumin solution in ethanol (2.424 mg/mL) was mixed with the gel
components (i.e., collagen II, HA and PEG) and the mixture was then incubated at 37 ◦C.
2.5. Rheological Study of Blank CO–HA Gels and NP/CO–HA Gel Composites
Rheological properties of blank CO–HA Gel composed of different MW PEG with or
without NP were determined using a TA Discovery HR-2 rheometer (TA Instruments, New
Castle, DE) with a cone shape geometry (40 mm, 2◦). After mixing three gel components
(i.e., collagen, HA and PEG) at the ratios described in Section 2.4, 800 µL of the mixture
was immediately loaded onto a sample loading plate pre-equilibrated at 25 ◦C. The cone
shape geometry was lowered to a pre-determined gap (48 µm) to obtain a vertical side wall.
Oscillation amplitude analysis was performed at 37 ◦C to determine a linear viscoelastic
region (LVR) at a frequency of 1 Hz. Gelling time of hydrogels was determined via time
sweep with 1 Hz frequency and 5% strain in 20 min at 37 ◦C. Storage modulus of the CO–
HA Gel was obtained by unconfined compression measurements with oscillation frequency
ranging from 0.1 to 10 Hz at 5% strain at 37 ◦C. The CO–HA Gel and NP/CO–HA Gel
composites were placed between a solid plate and the rheometer geometry, and freely
expanded laterally during the dynamic compression. The measurements were carried out
in triplicate.
2.6. Crosslinking Density Study
The crosslinking degree of the CO–HA Gel was calculated based on the rubber elas-
ticity theory using experimental storage modulus G’ as reported previously [44]. The
number of elastically active junctions in the network per unit of volume (ne, mol/m3) was
calculated using the following Equation (2):
G′ = neRT (2)
where G′ is storage modulus, R is the gas constant, and T is the absolute temperature.
2.7. Determination of Swelling Property
Disc-shaped CO–HA Gel samples were formed in a 96-well plate in triplicate. The
sample was transferred into an Eppendorf tube and weighed on a microscale (Mettler
Toledo, Greifensee, Switzerland) to obtain the initial weight (Wi). The sample was then
immersed in saline and incubated at 37 ◦C to allow free swelling for 48 h. The sample
was taken out and excess saline was gently removed. Fully swollen samples (Ws) were
weighed on a microscale and lyophilized (FreeZone Triad Cascade Benchtop Freeze Dryer,
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LABCONCO, Kansas City, MO, USA). Hydrogel swelling was calculated based on mass
change percentage (%) using the following equation:




The weight (Wd) of the freeze-dried hydrogels was also determined, and the equilib-





2.8. Morphology/Internal Structure of Cur NP and NP/CO–HA Gel Composites
Lyophilized Cur NP was transferred to a metal substrate with double-sided carbon
tape. A thin film of Au was sputtered coated onto the NP for 30 s. The sample was then
imaged using SIGMA VP Field Emission-scanning electron microscope (FE-SEM) (ZEISS,
Oberkochen, Germany). Hydrogel samples were imaged via cryo-SEM. The blank CO–HA
Gel sample was formed and frozen in liquid nitrogen and attached to the specimen holder
of a cryo-transfer system. The sample was transferred onto a cryostage in the SEM system
and cross-sectioned, and subsequently transferred to a SEM sample stage and examined
via FE-SEM. The structure of Cur NP/CO–HA Gel composite was also examined using
cryo-transmission electron microscopy (cryo-TEM). Small pieces of Cur NP/CO–HA Gel
composite were transferred on a TEM copper grid. The grid was quickly immersed in liquid
ethane. The frozen-hydrated specimens were mounted on a cryo-holder and observed
using JEM-2100 TEM (JEOL USA, Inc, Peabody, MA, USA). The obtained images were
analyzed by image J find edge process and threshold. The % of mesh area and mesh size
were analyzed by area fraction and ferret’s diameter function, respectively. Mesh size
diameters D90, D50, and D10 were obtained by excel percentile function. Diameter span





2.9. In Vitro Degradation Study
In vitro degradation of CO–HA Gels was investigated by incubating formed hydrogels
(300 µL) in 300 µL of saline at 37 ◦C in triplicate. At pre-determined time intervals, the
hydrogels were removed and gently washed with DI water. The remaining free amine
groups in the hydrogel were determined using a spectrophotometric method [45,46]. Briefly,
187 µL of 0.1% (w/v) TNBS diluted with 0.1 M NaHCO3 were added into the hydrogel
samples and incubated for 2 h at 37 ◦C. The reaction was ceased by adding 563 µL of 6 N
HCl to the samples followed by autoclave for 1 h at 120 ◦C. After the samples were cooled
down to room temperature, the mixture was then spectrophotometrically measured at
an absorbance wavelength of 340 nm using a microplate-reader (Spectramax M2 Multi-
Mode microplate reader, Molecular Devices, LLC, San Jose, CA, USA). The free amine
group content was calculated based on a standard curve prepared using glycine standards.
The total free amine group content (ConTotal) was determined using the same amount of
collagen II prior to the degradation study. Percentage (%) of free amine groups in the
formed hydrogel was calculated based on the Equation (6):




In vitro degradation of CO–HA Gels (300 µL) was also studied in the presence of
enzymes, including 22.5 U (75 U/mL) collagenase and 5 U (16.7 U/mL) hyaluronidase
in 300 µL of saline at 37 ◦C in triplicate. The hydrogels incubated in saline without the
presence of enzymes at 37 ◦C were studied as control group.
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2.10. In Vitro Release Study of Cur NP/CO–HA Gel Composites
In vitro curcumin release characteristics from Cur NP/CO–HA Gel composites were
studied in triplicate. The composite (200 µL) was immersed in 200 µL of saline containing
10% (w/v) Tween 80, 0.1% (w/v) NAC, and 0.01% (w/v) BHT, and incubated at 37 ◦C in a
water bath with shaking at 45 rpm. At pre-determined time points, 150 µL of release media
was withdrawn and replenished with fresh media. The released curcumin amount was
analyzed by HPLC. The percentage of cumulative curcumin released was calculated.
2.11. In Vitro Anti-UM Study of Cur NP/CO–HA Gel Composites
Anti-UM study of Cur NP/CO–HA Gel composite was conducted by using transwell
insert (6.5 mm diameter with 8.0 µm pore polyester membrane, Corning Life Sciences,
Corning, NY, USA). MP-38 cells were seeded in a 24-well plate (8 × 104 cells per well) and
incubated for 24 h till confluency reached around 80%. Cur NP/Gel 1, BLK NP/Gel 1,
Cur/Gel 1 and Cur NP suspension (curcumin concentration: 201.0 µg/mL) were tested.
The gel mixture (100 µL) was transferred into a transwell insert chamber and incubated in
a 37 ◦C incubator to form the composites. The insert was then placed in the 24-well plate
seeded with MP-38 cells and completely immersed in the culture medium. For the Cur
NP suspension group, 100 µL of suspension (without hydrogel components) was added
into a transwell insert before the insert was placed into a 24-well plate. The cells seeded
on the 24-well plate with the transwell inserts containing different treatments were then
cultured at 37 ◦C for 3 days. Following the treatment, the transwell inserts were removed
and cells were washed with PBS three times. CyQUANT® MTT reagents (Thermo Fisher
Scientific, Waltham, MA, USA) were prepared and added into the 24-well plate following
the manufacturer’s protocol. The absorbance of the samples at 570 nm was determined
using a microplate reader. MP-38 cells without any treatment grown in the RPMI-1640
medium were studied as control. Cell viability was calculated based on the equation below:





In order to further demonstrate the anti-UM effect was due to the sustained curcumin
release from the NP/CO–HA Gel composites, MP-38 cells were directly cultured on the
surface of the CO–HA Gels and BLK NP/CO–HA Gel composites. MP-38 cells directly
grown in a culture plate without Gels was studied as control. Tested composites (40 µL)
were mixed at the ratios described in Section 2.4 and transferred into a 96-well plate. The
96-well plate was incubated at 37 ◦C for 30 min. After the CO–HA Gel and composites were
well formed, 150 µL of RPMI-1640 medium without FBS was added into the wells and in-
cubated for 2 h at 37 ◦C. The medium was then removed and replaced with 150 µL of fresh
RPMI-1640 medium contained 20% FBS and 1% penicillin-streptomycin before seeding
MP-38 cells (1.5 × 104 cell per well) on the surface of the CO–HA Gel or blank NP/CO–HA
Gel composites. At pre-determined timepoints, cells were stained with LIVE/DEAD assay
following the manufacturer’s instruction and imaged by EVOS® FL Auto Cell Imaging Sys-
tem (Thermo Fisher Scientific, Waltham, MA, USA) via GFP, TexasRed, and Transmission
channels. Cell number was quantified by Image J. Cell viability was calculated based on
the equation below:
Cell viability (%) =
(
Cell numberLive (GFP)




All data was collected and presented as mean ± S.D. (standard deviation). Statis-
tical analysis was performed using Student’s t-test with p < 0.05 as the minimal level
of significance.
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3. Results and Discussion
3.1. Characteristics of NP
As shown in Table 1, NP with (Cur NP) or without curcumin (BLK NP) was 161.9 ±
5.1 nm and 156.6 ± 1.5 nm in size with a narrow particle size distribution (PDI < 0.1),
respectively. BLK and Cur NP were negatively charged with a zeta potential around−26 to
−28 mV. Due to the abundant presence of negatively charged HA in the vitreous chamber,
the negative surface charge of Cur NP was considered to be favorable, as it can avoid
charge trapping and maintain NP mobility to facilitate drug delivery to the target posterior
segments (e.g., choroid).
Table 1. Particle size, size distribution and surface charge of polymeric nanoparticles (NP) (n = 3).
Sample Size (nm) PDI Zeta Potential (mV)
Blank (BLK) NP 161.9 ± 5.1 0.074 ± 0.031 −26.1 ± 2.0
Lyophilized BLK NP 159.7 ± 2.2 0.069 ± 0.024 −27.5 ± 1.0
Curcumin (Cur) NP 156.6 ± 1.5 0.056 ± 0.027 −27.9 ± 1.2
Lyophilized Cur NP 163.4 ± 1.0 0.070 ± 0.021 −31.2 ± 0.2
In order to ensure long-term storage stability of Cur NP and to fabricate NP/CO–HA
Gel composites, dry NP was obtained via lyophilization. During the lyophilization process,
the pre-frozen step induced water crystal that can disrupt the stabilizer shell around NP,
resulting in clustering during the reconstitution step [47]. Accordingly, various cryopro-
tectants (i.e., trehalose, mannitol, and sucrose) at different cryoprotectant to NP weight
ratios were investigated. Among all the cryoprotectants studied, sucrose demonstrated
superior cryoprotective effect against nanoparticle aggregation during the lyophilization
process and hence was selected as the cryoprotectant. As shown in Table 1, NP remained
similar particle size and zeta potential following the reconstitution process when sucrose
was used at a NP/sucrose weight ratio of 25:1. Curcumin loading of the lyophilized Cur
NP was 0.20 ± 0.004% (w/w) (n = 3). The reported IC50 of curcumin NP against cancer
and metastatic cancer cells (e.g., pancreatic, ovarian, metastatic breast) was in the range of
10–15 µM [48,49]. Therefore, it is considered that our NP had sufficient curcumin loading.
In addition, the value IC50 of Cur NP against MP-38 cells was about 19% lower than
that of the first-line treatment dacarbazine group (data not shown). The morphology of
lyophilized Cur NP was shown in Figure 1a. The NP showed a spherical shape with a
homogenous size distribution (around 85.8 ± 15.6 nm). It was expected that the particle
size observed via SEM was smaller than the hydrodynamic diameter determined via DLS.
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Figure 1. (a) Scanning electron microscope (SEM) image of curcumin nanoparticles (Cur NP). (b) 
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drogel composite. Arrows indicate Cur NP; * TEM cooper grid, ** Gel composite. 
Figure 1. (a) Scanning electron microscope (SEM) image of curcumin nanoparticles (Cur NP). (b) Rep-
resentative cryogenic transmission electron microscope (Cryo-TEM) image of the Cur NP/hydrogel
composite. Arrows indicate Cur NP; * TEM cooper grid, ** Gel composite.
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3.2. Characteristics of CO–HA Gels
Two 8-arm PEG’s were used to prepare our hydrogel Gel 1 (MW: 20 kDa) and Gel 2
(MW: 40 kDa), respectively. It can be seen in Figure 2a that the CO–HA Gel mixture was
in a liquid state at room temperature. Following incubation at 37 ◦C (body temperature),
the mixture quickly crosslinked between succinimidyl groups of 8-arm PEG and primary
amine groups of collagen to form a transparent semisolid gel (Figure 2b). The developed
CO–HA Gel with good luminous transmittance (>98%) that was close to water (Figure S1a).
To fabricate NP-loaded hydrogel composite, NP was mixed into the CO–HA Gel mixture
prior to the gelation process. As shown in Figure 1b, NP with a spherical shape was
homogeneously distributed in the CO–HA Gel composite matrix. The optical properties
of NP incorporated CO–HA Gel composites was also studied (supplementary materials).
The presence of a high dose NP in the NP/Gel composites resulted in a decrease in
the luminous transmittance compared to the control (DI water) and CO–HA Gel group
(Figure S1a). The luminous transmittance of the Cur NP/Gel composite between 380 and
480 nm was decreased, as curcumin has light absorbance at around 430 nm, but it was
higher than that of the BLK NP/Gel composite when the wavelength was above 500 nm.
Whether the presence of yellowish curcumin would potentially impair the visual process
will be further investigated and discussed following an in vivo anti-UM dose optimization
study in the future. Nevertheless, the Gel and NP/Gel composites studied can maintain
good transparence as shown in Figure S1b.
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. . . Rheological Properties
The gelling time of blank CO–HA Gels was determined using a time sweep at 37 ◦C.
Both CO–HA Gel 1 and Gel 2 showed a short gelling time around or below 1 min at 37 ◦C.
This confirmed that the developed CO–HA Gel can quickly transform from a liquid state
to a semisolid gel state at body temperature. The CO–HA Gel 1 with a lower MW PEG had
a shorter gelling time (32.37 ± 3.44 s) than that (58.66 ± 9.33 s) of the CO–HA Gel 2 with a
higher MW PEG (Figure 3a,b). The same amount of collagen can crosslink with low MW
PEG with a higher number of reactive groups in shorter duration [26]. The presence of Cur
NP resulted in a slight increase in gelling time, but the impact was not significant. The
NP/CO–HA Gel 1 and NP/CO–HA Gel 2 composites had a gelling time of 40.39± 9.21 and
63.64± 5.21 s, respectively (Figur 3b). Overall, Gel 1 and NP/ – A Gel 1 composite had
a significant shorter gelling time compared with Gel 2 and NP/CO–HA Gel 2 composite
(p < 0.05), respectively.
The mechanical properties of CO–HA Gels and NP/Gel composites were studied
using unconfined compression testing. All the testing samples were evaluated in a LVR
(0.5% to 20% strain). The average storage moduli of Gel 1 and Gel 2 determined based
on the oscillation frequency method were 182.26 ± 3.93 and 166.84 ± 20.26 Pa (p > 0.05),
respectively (Figure 4a,b). The presence of NP had a stronger effect on the storage modulus
(69.54 ± 10.10 Pa) of the NP/Gel 2 composite, compared to that (148.96 ± 19.15 Pa) of
the NP/Gel 1 composite. The crosslinking density of Gel or its NP/Gel composite was
calculated based on their storage moduli. Gel 2 had a slightly lower crosslinking density
(0.064 ± 0.008 mol/cm3) than Gel 1 (0.071 ± 0.002 mol/cm3), which can be explained
Pharmaceutics 2021, 13, 1335 9 of 19
by the less functional succinimidyl groups present in the higher MW PEG. Overall, the
presence of NP resulted in a decrease in crosslinking density for both NP/Gel 1 and
NP/Gel 2 composites (0.058 ± 0.007 mol/cm3 and 0.027 ± 0.004 mol/cm3, respectively).
The presence of NP in the Gel mesh matrix may increase distance between polymer
chains, thus decreasing the storage modulus [50]. The Gel 2 composite with a higher
MW had higher collagen mobility and less reactive groups [26]. The presence of NP may
further inhibit crosslinking, resulting in significant decrease in the storage modulus of the
Gel 2 composite.




Figure 3. (a) Rheological properties of Gel 1, Gel 2 and nanoparticles (NP)/Gel composites obtained via time sweep with 
1 Hz frequency and 5% strain at 37 °C (n = 3). (b) Gelling time of the different Gel and its NP/Gel composite (n = 3). 
Statistical analysis comparing between Gels or NP/Gel composites, *, # p < 0.05. 
The mechanical properties of CO–HA Gels and NP/Gel composites were studied us-
ing unconfined compression testing. All the testing samples were evaluated in a LVR 
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(69.54 ± 10.10 Pa) of the NP/Gel 2 composite, compared to that (148.96 ± 19.15 Pa) of the 
NP/Gel 1 composite. The crosslinking density of Gel or its NP/Gel composite was calcu-
lated based on their storage moduli. Gel 2 had a slightly lower crosslinking density (0.064 
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sites (0.058 ± 0.007 mol/cm3 and 0.027 ± 0.004 mol/cm3, respectively). The presence of NP 
in the Gel mesh matrix may increase distance between polymer chains, thus decreasing 
the storage modulus [50]. The Gel 2 composite with a higher MW had higher collagen 
mobility and less reactive groups [26]. The presence of NP may further inhibit crosslink-
ing, resulting in significant decrease in the storage modulus of the Gel 2 composite. 
Overall, storage moduli of the CO–HA Gels and NP/CO–HA Gel composites were in 
a range of 55 to 200 Pa, which was comparable to many soft tissues including the human 
vitreous body (0.24–14.5 Pa) [51] and similar to the reported hydrogels studied as an arti-
ficial vitreous body [52]. In addition, our CO–HA Gel system with high viscosity (22.6 ± 
2.73 Pa.s and 10.9 ± 1.59 Pa.s at 37 °C for NP/CO–HA Gel 1 and Gel 2, respectively) can 
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1.46), indicating that the meshes of Gel 2 had a wider mesh size distribution. It has been 
reported that the component and composition of a hydrogel and crosslinking density can 
influence hydrogel mesh size [28]. Considering that the difference in crosslinking density 
of Gel 1 and Gel 2 was not significant (p > 0.05), PEG MW appeared to play a significant 
role in the mesh size distribution. The high MW PEG with a longer polymer chain may 
lead to the formation of interpenetrating polymer networks and hence smaller meshes. 
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Overall, storage moduli of the CO–HA Gels and NP/CO–HA Gel composites were
in a range of 55 to 200 Pa, which was comparable to many soft tissues including the
human vitreous body (0.24–14.5 Pa) [51] and similar to the reported hydrogels studied as
an artificial vitreous body [52]. In addition, our CO–HA Gel system with high viscosity
(22.6± 2.73 Pa·s and 10.9± 1.59 Pa·s at 37 ◦C for NP/CO–HA Gel 1 and Gel 2, respectively)
can increase the viscoelasticity of the vitreous body is unlikely cause turbulent flow in the
human vitreous humor and [51,53], thus reducing the risk of retinal re-detachment. This
indicated that the developed in situ gelling hydrogels and NP/hydrogel composites may
be well tolerated in these soft tissues. In vivo compatibility will be studied using an animal
model in the future.
3.2.2. Internal Structure and Morphology of CO–HA Gels
The internal structure of CO–HA Gel 1 and Gel 2 was characterized using cryo-SEM.
As shown in Figure 5, Gel 2 showed a slightly smaller mesh area (70.66± 3.56%) and median
mesh diameter (D50: 7.67 µm) than Gel 1 (mesh area: 73.70 ± 2.93% and D50: 9.89 µm,
Table 2). In addition, Gel 2 had a higher mesh size span value (1.89) than Gel 1 (span value:
1.46), indicating that the meshes of Gel 2 had a wider mesh size distribution. It has been
reported that the component and composition of a hydrogel and crosslinking density can
influence hydrogel mesh size [28]. Considering that the difference in crosslinking density
of Gel 1 and Gel 2 was not significant (p > 0.05), PEG MW appeared to play a significant
role in the mesh size distribution. The high MW PEG with a longer polymer chain may
lead to the formation of interpenetrating polymer networks and hence smaller meshes.
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Table 2. Mesh size of Gel 1 and Gel 2.
el
Mesh Diameter (µm) Mesh Area
(%)D10 D50 D90 Span
Gel 1 5.70 9.89 20.13 1.46 73.70 ± 2.93
Gel 2 3.84 7.67 18.36 1.89 70.66 ± 3.56
Pharmaceutics 2021, 13, 1335 11 of 19
3.2.3. Swelling Property and Equilibrium Water Content
The swelling property and EWC of CO–HA Gels were also studied. Overall, our
CO–HA Gels showed relatively low swelling (below 10%). Gel 1 with a higher crosslinking
density exhibited less swelling (8.29 ± 0.37%) than Gel 2 (13.84 ± 3.61%) with a lower
crosslinking density (Figure 6). The swelling of hydrogels inevitably causes decrease in
mechanical strength, morphology changes, and bulk degradation [54,55]. In addition,
swollen hydrogel may cause not only slippage from the implantation or injection site but
also tissue compression [56]. Therefore, our CO–HA gel system with low swelling in the
aqueous environment is considered desirable in achieving prolonged drug release while
maintaining good compatibility with surrounding tissues. The calculated EWC of CO–HA
Gel 1 and Gel 2 was 96 ± 0.12% and 97 ± 0.3%, respectively, which were very similar to
that of HA hydrogel reported previously (EWC ranging from 60–99%) [57–59]. The water
content of the human body is around 60% [60] and that of the eye vitreous body is around
98% [61]. Accordingly, our CO–HA Gels with similar fluid content to living tissues may
have excellent tissue compatibility.
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3.3. In Vitro Degradation of CO–HA Gels
In vitro degradation behavior of CO–HA Gel 1 and Gel 2 was studied in saline at 37 ◦C.
CO–HA Gel was formed through ester linkers between PEG and collagen II and the ester
linkers are susceptible to hydrolytic degradation. Therefore, the non-crosslinked free amine
groups determined using the TNBS assay can indirectly reflect the crosslinking degree
between PEG and collagen when compared with collagen alone [46,62]. The changes in free
amine groups of Gel 1 and Gel 2 were monitored during a 4-week degradation study. The
initial free amine group percentage of Gel 1 and Gel 2 without degradation was 3.9 ± 1.02%
and 24.4 ± 2.45%, respectively. The lower amount of free amine groups in Gel 1 than
Gel 2 confirmed the higher crosslinking degree of Gel 1 than Gel 2, which was consistent
with the crosslinking density results described in Section 3.2.1. As shown in Figure 7, the
percentage of free amine groups of both Gels gradually increased with the degradation of
the hydrogels over 4 weeks. Gel 1 and Gel 2 had 47.6 ± 1.02% and 68.0 ± 3.21% free amine
groups by day 28, respectively. There was no obvious gel structure change observed for
both Gels. These results indicated that slow degradation behavior of the developed in situ
CO–HA Gels, which can be used to achieve sustained payload release.
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Figure 7. Percentage (%) of free amine groups in CO–HA Gels during in vitro degradation testing in
saline at 37 ◦C over four weeks (n = 3).
Collagenase and hyaluronidase are the main enzymes exist in the human body that
can degrade collagen and hyaluronic acid, respectively. Therefore, in vitro degradation of
CO–HA Gel was also studied in the presence of collagenase (75 U/mL) and hyaluronidase
(16.7 U/mL). The high concentration collagenas can completely degrade Gel 1 and Gel 2
in 7 and 3 days, r spectively. Under he neutr l vironments, the activity of hyaluronidase
was largely ecreased [63]. As a result, no obvio s degradatio was observed for Gel 1 and
Gel 2 following a 7-day incubation of high concentration hyaluronidase (data now shown).
It is worth mentioning that both collagenase and hyaluronidase are not abundant in the
human vitreous humor [64,65]. Accordingly, the hydrolytic degradation may be the main
degradation pathway of our CO–HA Gel. The degradation of CO–HA Gel in the vitreous
humor will be studied using an animal model in the future.
3.4. In Vitro Release Characteristics of Cur NP/CO–HA Gel Composites
In vitro release characteristics of the Cur NP/Gel composites were studied in the
presence of stabiliz rs including 10% (w/v) Tween 80, 0.1% (w/v) NAC, and 0.01% (w/v)
BHT to minimize curcumin degradation during long-term release studies [66,67]. As
shown in Figure 8a, curcumin slowly released from the Cur NP/Gel 1 composite and about
55% curcumin was released over four weeks, whereas the Cur NP/Gel 2 composite had
a relatively higher curcumin release in the first two days, which may be due to higher
swelling of Gel 2 and hence faster payload diffusion and higher initial curcumin release.
With respect to the Cur NP/Gel 2 composite, curcumin release was slowed d wn after day
5 and reac d a plateau in 10 days. The cumulative curcumin released was around 43% by
the end of four weeks. Overall, the NP/Gel 1 composite showed better sustained curcumin
release behavior. This may be attributed to its higher portion of large meshes through
which payload can transport to the release medium (Table 2). In order to demonstrate
whether intact NP can be released from the composite, release samples collected were
imaged via Cryo-TEM. As shown in Figure 8c, spherical Cur NP was observed in the day-5
release samples, and the released Cur NP showed a similar particle size compared to that
of the control group (NP suspended in water) (Figure 8d). These results demonstrated that
intact Cur NP can be sustained released from our CO–HA Gels, which may lead to better
transport of curcumin in the vitreous humor to reach its target posterior site (i.e., choroid).
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over the first 20 days. The weight loss of the Cur NP/Gel 2 composite reached a plateau at 
around day 23, whereas a gradual weight loss was observed for the Cur NP/Gel 1 compo-
site over four weeks. This was consistent with the sustained curcumin release from the 
Cur NP/Gel 1 composite. The Cur NP/Gel 1 composite with a better sustained curcumin 
release profile was selected for the anti-UM effect study. 
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The weight loss of the Cur NP/Gel composites was also monitored during the release
study. It can b seen in Fig 8b that both NP/Gel comp sites had a similar weight loss
over the first 20 days. The weight loss of the Cur NP/Gel 2 composite reached a plateau
at around day 23, whereas a gradual weight loss was observed for the Cur NP/Gel 1
composite over four weeks. This was consistent with the sustained curcumin release
from the Cur NP/Gel 1 composite. The Cur NP/Gel 1 composite with a better sustained
curcumin release profile was selected for the anti-UM effect study.
3.5. In Vitro Anti-UM Effect of Cur CO–HA Gel Composites
A “proof-of-concept” short-term in vitro cell study for 3 days was conducted due to the
challenges in culturing cells for prolonged duration (e.g., 30 days). Cur NP amount loaded
into Gel 1 was determined based on curcumin IC50 and release beh vior from the Cur
NP/Gel composite (Figure 8a). Compared to the Cur/Gel 1 (cell viability: 107.3 ± 2.57%)
and BLK NP/Gel 1 groups (cell viability: 93.8 ± 8.32%), the developed Cur NP/Gel 1
showed significantly decreased cell viability (52.7 ± 2.86%) (p < 0.01) (Figure 9). The
result demonstrated that sustained curcumin release from the Cur NP/Gel 1 composite
successfully inhibited UM cell growth. The poor anti-UM efficiency of the Cur/Gel 1
group may be resulted from the poorly water solubility and instability of curcumin in
the aqueous environment (pH > 7) [68], thus the lack of sustained therapeutic effect [69].
The Cur NP group (NP alone) showed significantly lower cell viability (29.8 ± 9.04%)
compared to the Cur NP/Gel 1 composite group, as the Cur NP amount was the same
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as that loaded in Cur NP/Gel 1 composite for a 30-day treatment instead of cur amount
released in the first 3 days. It has been reported that curcumin can down regulate HIF-1α
pathway [68]. A significant decrease in HIF-1α mRNA expression level of MP-38 cells
following the treatment of Cur NP for 24 h under hypoxia conditions was observed via
RT-qPCR (p < 0.05) (data not shown). This result suggested that downregulation of HIF-1α
pathway could be one of the reasons for anti-UM effect of Cur NP.
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to sustained Cur release from the Cur NP/Gel composite. Despite that the hydrogel com-
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* p < 0.01, **** .
As shown in Figure 10, the MP-38 cells grown on the surface of the Gel 1 and BLK
NP/Gel 1 composites had above 80% live cells during a period of 7 days, indicating low
cytotoxicity. UM cells grown on culture plate was studied as a control and showed a
significantly high live cell numbers compared to the Gel groups (p < 0.05) as culture plate
has more even surface compared to hydrogel surfaces. It can be seen in Figure 10a that
the cells grown on Gel 1 and BLK NP/Gel 1 composite had very similar morphology and
live cell numbers (%), suggesting that the incorporated our PLGA NP did not decrease
Gel’s cell compatibility. The low cytotoxicity of the CO–HA Gel 1 and its composite can be
attributed to the excellent biocompatibility of the hydrogel components (i.e., collagen, HA).
This result confirmed that the excellent anti-UM effect showed in Figure 9 was attributed
to ustained Cur r lease from the Cur NP/Gel compo ite. Despite that the hydrogel
components (i.e., coll g n and hyaluronic acid) have excellent biocompatibility and ood
ocular safety of curcumin has been previously demonstrated using cell lines such as human
retinal pigmented epithelial (D407) cells [70], 661W and ARPE-19 retinal cells [71], the
ocular safety of the developed Cur NP/Gel composite needs to be investigated using an
animal model in the future.
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4. Conclusions
The present research developed a long-acting, injectable, in situ gelling hydrogel
delivery platform inspired by the nature components of the vitreous body. The in situ
gelling hydrogel composed of nature occurring polymers collagen and hyaluronic acid
demonstrated excellent biocompatibility and can gel within minutes at the body tempera-
ture. In addition, the in situ gelling hydrogel with low swelling and soft storage modulus
degraded slowly and was capable of sustained release payload over four weeks. More
importantly, the curcumin nanoparticle/in situ hydrogel composite demonstrated excellent
anti-UM effect in a short-term anti-UM effect study. These results demonstrated the great
potential of the developed nanoparticle/in situ hydrogel composite for sustained treatment
of uveal melanoma in the posterior chamber. The biodistribution in ocular tissues (e.g.,
choroid and retina) and anti-UM effect and safety (e.g., tissue compatibility and intraocular
pressure) of the developed Cur NP/Gel composite need to be further studied using an
animal model.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13091335/s1, Figure S1: (a) Optical transmittance spectra and (b) photo of
CO–HA Gel 1 and NP/Gel 1 composites in a 96-well plate with a 125 µm sample thickness. Water
was studied as a control. References [72,73].
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